MedPath

Flexible Reinforced Laryngeal Mask Airway Versus Endotracheal Tube for Childhood Adenotonsillectomy

Phase 2
Completed
Conditions
Anesthesia Intubation Complication
Children
Adenotonsillectomy
Airway
Registration Number
NCT06356298
Lead Sponsor
Maternal and Child Health Hospital of Hubei Province
Brief Summary

The goal of this clinical trial is to compare the airway management effects of flexible reinforced laryngeal mask and endotracheal tube in childhood adenotonsillectomy.

Participants will be randomly allocated to two groups: endotracheal tube group (ETT) and flexible reinforced laryngeal mask group (FLMA). For those in ETT group: they will be intubated after induction of anesthesia .For those in FLMA group: they will be put in flexible reinforced laryngeal mask after induction of anesthesia .

The investigators will compare FLMA with ETT to see if flexible reinforced laryngeal mask can be used safely and effectively in childhood adenotonsillectomy,and if there will be less severe adverse events in FLMA.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • patients who choose to have adenotonsillectomy surgery
  • the American Society of Anesthesiologists (ASA) physical status ranked I-II
  • the oropharyngeal anatomy is normal
  • competent to provide informed consent
Exclusion Criteria
  • upper respiratory tract infection one week before surgery
  • oropharyngeal anatomy is abnormal
  • high risk of reflux aspiration
  • liver or kidney failure
  • psychiatric disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Peak airway pressureintraoperative period,10 minutes-1 hours

Maximum peak airway pressure during surgery

Petco2intraoperative period,10 minutes-1 hour

Petco2 at the end of surgery

Ventilation leakage or notintraoperative period,10 minutes-1 hour

Using volume ventilation, tidal volume set to 10 ml /kg, Ventilation leakage is defined as reaching more than 20% of the set tidal volume.

Secondary Outcome Measures
NameTimeMethod
Mean arterial pressure (MAP)Intraoperative period, 30 minutes - 1.5 hours

MAP level will be monitored and recorded at 6 time points, including the entry into the operation room (Time 0), 2 min after anesthesia induction (Time 1), implantation of FLMA or ETT (Time 2), implantation of mouth opener (Time 3) ,at the end of surgery (Time 4), and after removal of FLMA or ETT (Time 5)

Heart rate (HR)Intraoperative period, 30 min - 1.5 hours

HR will be monitored and recorded at 4 time points, including the entry into the operation room (Time 0), 2 min after anesthesia induction (Time 1), implantation of FLMA or ETT (Time 2), implantation of mouth opener (Time 3) ,at the end of surgery (Time 4), and after removal of FLMA or ETT (Time 5)

Extubation timePostoperative 30 minutes

Time to extubate, defined as occurrence of regular respiration from the end of the procedure.

Success of FLMA or ETTIntraoperative period, 10 minutes - 1hour

The first success of FLMA or ETT rate will be recorded, and insertion over three times will be considered as failed intubation.

Surgeon satisfactionPostoperative 30 minutes

Record the satisfaction of the surgeon with the FLMA or ETT, defined as a score out of100.

Recovery timePostoperative 30 minutes

Time to fully awake, defined as by a modified Aldrete score which will be recorded every 3 minutes from the end of the procedure with a recovery index (MAS) of 9 or more.

Dosage of anestheticIntraoperative period, 30 minutes - 1.5 hours

The total amount of sedative and analgesic drugs will be recorded.

Adverse eventsPostoperative 1 hour

The adverse events will be monitored and recorded during the operation and post-operation. AE will include: nausea and vomiting, reflux aspiration, hoarseness, dysphagia, sore throat, coughing, bronchospasm, laryngeal spasm, mask with blood, respiratory depression (defined as SpO2\< 90%),

Trial Locations

Locations (1)

Maternal and Child Health Hospital of Hubei Province

🇨🇳

Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath